Leland Gershell
Stock Analyst at Oppenheimer
(4.57)
# 249
Out of 5,130 analysts
151
Total ratings
50.7%
Success rate
33.45%
Average return
Main Sectors:
Stocks Rated by Leland Gershell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SPRB Spruce Biosciences | Initiates: Outperform | $283 | $79.99 | +253.79% | 1 | Dec 23, 2025 | |
| AARD Aardvark Therapeutics | Initiates: Outperform | $35 | $14.27 | +145.27% | 1 | Dec 23, 2025 | |
| CAPR Capricor Therapeutics | Maintains: Outperform | $22 → $54 | $23.84 | +126.51% | 6 | Dec 8, 2025 | |
| TRVI Trevi Therapeutics | Maintains: Outperform | $23 → $24 | $11.18 | +114.67% | 4 | Nov 14, 2025 | |
| ENGN enGene Holdings | Reiterates: Outperform | $30 → $33 | $8.81 | +274.57% | 3 | Nov 12, 2025 | |
| XERS Xeris Biopharma Holdings | Maintains: Outperform | $18 | $7.93 | +126.99% | 6 | Nov 7, 2025 | |
| VRDN Viridian Therapeutics | Maintains: Outperform | $32 → $36 | $31.73 | +13.46% | 7 | Oct 21, 2025 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Outperform | $73 → $87 | $53.25 | +63.38% | 8 | Sep 30, 2025 | |
| TECX Tectonic Therapeutic | Initiates: Outperform | $80 | $20.57 | +289.01% | 1 | Sep 3, 2025 | |
| SLNO Soleno Therapeutics | Maintains: Outperform | $105 → $110 | $43.00 | +155.81% | 9 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $61 | $77.25 | -21.04% | 3 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $490 | $398.29 | +23.03% | 8 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $20 | $10.54 | +89.75% | 1 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $76 → $110 | $101.02 | +8.89% | 2 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $215 → $224 | $202.99 | +10.35% | 12 | Jun 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 → $31 | $21.25 | +45.88% | 11 | Jun 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $10 | $5.03 | +98.81% | 1 | Jun 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $704 → $708 | $788.49 | -10.21% | 7 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $10 | $2.69 | +271.75% | 1 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $98 | $58.95 | +66.24% | 3 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $52 | $38.19 | +36.16% | 2 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $135 → $147 | $206.54 | -28.83% | 2 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $50 | $2.39 | +1,992.05% | 8 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $47 → $53 | $26.03 | +103.61% | 3 | Oct 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $3.68 | +226.09% | 2 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30,000 → $5,000 | $3.37 | +148,267.95% | 9 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $25 | $5.75 | +334.78% | 3 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $20 | $5.85 | +241.88% | 5 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $29 | $22.72 | +27.64% | 3 | Jun 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $35 | $16.95 | +106.49% | 2 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 | $0.36 | +2,673.93% | 1 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $23 → $20 | $1.07 | +1,769.16% | 3 | Nov 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $13 | $2.04 | +537.25% | 3 | Apr 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $150 → $120 | $4.00 | +2,900.00% | 1 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $6.40 | - | 1 | Oct 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | n/a | $32.01 | - | 2 | Nov 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $1.10 | +4,445.45% | 1 | Oct 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Perform | n/a | $15.82 | - | 5 | Mar 31, 2020 |
Spruce Biosciences
Dec 23, 2025
Initiates: Outperform
Price Target: $283
Current: $79.99
Upside: +253.79%
Aardvark Therapeutics
Dec 23, 2025
Initiates: Outperform
Price Target: $35
Current: $14.27
Upside: +145.27%
Capricor Therapeutics
Dec 8, 2025
Maintains: Outperform
Price Target: $22 → $54
Current: $23.84
Upside: +126.51%
Trevi Therapeutics
Nov 14, 2025
Maintains: Outperform
Price Target: $23 → $24
Current: $11.18
Upside: +114.67%
enGene Holdings
Nov 12, 2025
Reiterates: Outperform
Price Target: $30 → $33
Current: $8.81
Upside: +274.57%
Xeris Biopharma Holdings
Nov 7, 2025
Maintains: Outperform
Price Target: $18
Current: $7.93
Upside: +126.99%
Viridian Therapeutics
Oct 21, 2025
Maintains: Outperform
Price Target: $32 → $36
Current: $31.73
Upside: +13.46%
Crinetics Pharmaceuticals
Sep 30, 2025
Maintains: Outperform
Price Target: $73 → $87
Current: $53.25
Upside: +63.38%
Tectonic Therapeutic
Sep 3, 2025
Initiates: Outperform
Price Target: $80
Current: $20.57
Upside: +289.01%
Soleno Therapeutics
Aug 7, 2025
Maintains: Outperform
Price Target: $105 → $110
Current: $43.00
Upside: +155.81%
Aug 6, 2025
Maintains: Outperform
Price Target: $60 → $61
Current: $77.25
Upside: -21.04%
Aug 4, 2025
Upgrades: Outperform
Price Target: $490
Current: $398.29
Upside: +23.03%
Jul 31, 2025
Initiates: Outperform
Price Target: $20
Current: $10.54
Upside: +89.75%
Jul 10, 2025
Maintains: Outperform
Price Target: $76 → $110
Current: $101.02
Upside: +8.89%
Jun 13, 2025
Maintains: Outperform
Price Target: $215 → $224
Current: $202.99
Upside: +10.35%
Jun 13, 2025
Maintains: Outperform
Price Target: $10 → $31
Current: $21.25
Upside: +45.88%
Jun 6, 2025
Initiates: Outperform
Price Target: $10
Current: $5.03
Upside: +98.81%
May 9, 2025
Maintains: Outperform
Price Target: $704 → $708
Current: $788.49
Upside: -10.21%
Mar 24, 2025
Initiates: Outperform
Price Target: $10
Current: $2.69
Upside: +271.75%
Feb 24, 2025
Upgrades: Outperform
Price Target: $98
Current: $58.95
Upside: +66.24%
Nov 11, 2024
Maintains: Outperform
Price Target: $48 → $52
Current: $38.19
Upside: +36.16%
Nov 8, 2024
Maintains: Outperform
Price Target: $135 → $147
Current: $206.54
Upside: -28.83%
Nov 5, 2024
Reiterates: Outperform
Price Target: $50
Current: $2.39
Upside: +1,992.05%
Oct 9, 2024
Maintains: Outperform
Price Target: $47 → $53
Current: $26.03
Upside: +103.61%
Sep 12, 2024
Reiterates: Outperform
Price Target: $12
Current: $3.68
Upside: +226.09%
Sep 3, 2024
Maintains: Outperform
Price Target: $30,000 → $5,000
Current: $3.37
Upside: +148,267.95%
Aug 12, 2024
Maintains: Outperform
Price Target: $30 → $25
Current: $5.75
Upside: +334.78%
Jul 10, 2024
Maintains: Outperform
Price Target: $14 → $20
Current: $5.85
Upside: +241.88%
Jun 6, 2024
Reiterates: Outperform
Price Target: $29
Current: $22.72
Upside: +27.64%
Apr 16, 2024
Upgrades: Outperform
Price Target: $35
Current: $16.95
Upside: +106.49%
Apr 9, 2024
Maintains: Outperform
Price Target: $10
Current: $0.36
Upside: +2,673.93%
Nov 15, 2023
Maintains: Outperform
Price Target: $23 → $20
Current: $1.07
Upside: +1,769.16%
Apr 12, 2023
Maintains: Outperform
Price Target: $16 → $13
Current: $2.04
Upside: +537.25%
Mar 24, 2023
Maintains: Outperform
Price Target: $150 → $120
Current: $4.00
Upside: +2,900.00%
Oct 4, 2022
Downgrades: Perform
Price Target: n/a
Current: $6.40
Upside: -
Nov 25, 2020
Initiates: Perform
Price Target: n/a
Current: $32.01
Upside: -
Oct 23, 2020
Initiates: Outperform
Price Target: $50
Current: $1.10
Upside: +4,445.45%
Mar 31, 2020
Upgrades: Perform
Price Target: n/a
Current: $15.82
Upside: -